Agenda

Friday, November 30, 2018

Prostate Brachytherapy

7:00 am	Registration and Continental Breakfast	
8:00	Welcome Albert Koong, MD	
8:05	Bending the Slope of the Brachytherapy Curve Clinical Management – New Brachytherapy Data Steven J. Frank, MD	
Clinical Manag	gement - New Brachytherapy Data	
8:15	Unfavorable High-Risk Disease Juanita M. Crook, MD, FRCPC	
8:25	Favorable High-Risk Disease Richard G. Stock, MD	
8:35	Unfavorable Intermediate-Risk Disease and Update on Ascende RT Trial Mira M. Keyes, MD, FRCPC	
8:45	Favorable Intermediate-Risk Disease and Update on RTOG 0232 Bradley R. Prestidge, MD, MS	
8:55	MD Anderson Phase II Trial of Monotherapy for Intermediate Risk Localized Disease Thomas J. Pugh, MD	
9:05	Focal Brachytherapy - When, How, and Why? Michael J. Zelefsky, MD	
9:15	Panel Discussion	
9:45	Break	
MRI-Assisted Radiosurgery (MARS) for HDR and LDR Brachytherapy		
10:00	MRI of the Prostate - Screening, Diagnosis, and Surveillance Setting Tharakeswara K. Bathala, MD	
10:10	MRI of the Prostate for the Brachytherapist Patrick W. McLaughlin, MD	
10:20	MARS for LDR Brachytherapy Steven J. Frank, MD	
10:30	MARS for HDR Brachytherapy Cynthia M. Menard, MD	
10:40	MRI-based Treatment Planning Systems and QA-LDR Rajat J. Kudchadker, PhD	
10:50	MRI-based Treatment Planning Systems and QA-HDR Firas M. Mourtada, PhD	
11:00	Optimizing MRI Sequences for Brachytherapy Jingfei M. Ma, PhD	

11:10	Panel Discussion	
11:45	Break	
12:00 pm	Lunch - Keynote Speaker Improving Prostate Brachytherapy Access for Veterans Michael P. Hagan, MD, PhD	
1:00	Brachytherapy for the VA Patient-The Process of Optimizing Care Jeffery A. Jones, MD	
1:20	Immunotherapy and Brachytherapy-Defining an Abscopal Effect Chandan M. Guha, MD, PhD	
1:30	Redefining the Brachytherapy Definition of Failure Howard Thames, PhD	
1:40	Management for Rising PSA Following Radiation Treatment Michael M. Ghilezan, MD, PhD	
1:50	Prostate Imaging During the Recurrent Setting Aradhana M. Venkatesan, MD	
2:00	Sexual Outcomes Data and Management Pierre M. Blanchard, MD PhD	
2:10	Optimizing Sexual Function After Brachytherapy Run Wang, MD	
2:20	Urinary Outcomes Data and Management William Graber, MD	
2:30	Rectal Outcome Data and Management Mitchell S. Anscher, MD	
2:40	The Use of Hydrogel Spacer in Brachytherapy: LDR, HDR Monotherapy, or Combination Treatment with IMRT or Protons Brian J. Davis, MD PhD	
2:50	Panel Discussion	
3:20	Break	
Building a Brachytherapy Practice		
3:30	The Road to LDR Brachytherapy Clinical Proficiency Chad M. Tang, MD	
3:40	The Road to HDR Brachytherapy Clinical Proficiency Anna M. Likhacheva, MD, MPH	
3:50	Essentials for Growing an LDR Practice John E. Sylvester, MD	
4:00	Essentials for Growing an HDR Practice Peter J. Rossi, MD	
4:10	Communicating Value in Prostate Brachytherapy Nikhil G. Thaker, MD	
4:20	Brachytherapy Advocacy and Payment Models Peter F. Orio, III, DO, MS	
4:30	What Defines a Medical Event in Brachytherapy Zoubir Ouhib, PhD	

4:40	Christopher Deufel, PhD
4:50	The Collaboration of ABS and Industry to Support Brachytherapy Programs Brett Cox, MD
5:00	Panel Discussion
5:15	Adjourn
6:00	Welcome Reception Good Co. Armadillo Palace

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audio taping, and videotaping are prohibited.